Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-696-3 | CAS number: 78605-96-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
OECD 421 (2010): No Observed Adverse Effect Level (NOAEL) of = 100 mg/kg bw/day for reproductive toxicity (a reduction of maternal body weight gain and feed consumption).
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2009-2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc.
- Age at study initiation: (P) Males: 85 days; Females: 79 days
- Weight at study initiation: (P) Males: 316-342 g; Females: 201-230 g
- Fasting period before study:no data
- Housing: P generation individually housed in steel wire-bottomed cages except during cohabitation and postpartum periods. From day 20 of presumed gestation female rats were housed individually in nesting boxes. Each dam and delivered litter were housed in a common nesting box during postpartum.
- Diet (e.g. ad libitum):ad libitum, Certified Rodent Diet #5002 (PMI Nutrition International)
- Water (e.g. ad libitum):ad libitum, mains sourced and filtered by reverse osmosis.
- Acclimation period:13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-26
- Humidity (%):30-70
- Air changes (per hr):at least 10
- Photoperiod (hrs dark / hrs light):12/12
IN-LIFE DATES: From: 17 Aug 2009 To: 2 Oct 2009 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Suspensions of test substance were prepared daily, stored at room temperature and protected from light.
VEHICLE
- Justification for use and choice of vehicle (if other than water): no data
- Concentration in vehicle: 3.125, 6.25, 12.5, 25mg/ml
- Amount of vehicle (if gavage): 4ml/kg
- Lot/batch no. (if required):J-145
- Purity:no data - Details on mating procedure:
- - M/F ratio per cage: 1
- Length of cohabitation: 7 days
- Proof of pregnancy: vaginal plug and/or sperm in vaginal smear referred to as day 0 of pregnancy
- After 7 days of not mated females will be considered to be at day 0 of presumed gestation
- After successful mating each pregnant female was caged individually. Also those female rats in presumed gestation.
- Any other deviations from standard protocol: none - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- by HPLC-UV, validated internal method.
- Duration of treatment / exposure:
- Male rats: total 45 days - from 14days before cohabitation, through cohabitation (7 days) and continuing through the day before sacrifice after completion of the dosage period.
Female rats: total 44 or 45 days - from 14 days before cohabitation, through cohabitation (7 days), and continuing through the day before sacrifice on postpartum day 5, or study day 46 (for rats that did not become pregnant) or gestation day 25 (for rats that did not deliver). Dams with no surviving pups were sacrificed on postpartum day 1.
Pups were not administered the test substance directly but may have been exposed in utero or via maternal milk. - Frequency of treatment:
- Once daily. Dosage volume was adjusted daily on the basis of individual body weights recorded before administration.
- Details on study schedule:
- - No selection of F1 parental animals took place
- Age at mating of the mated animals in the study: approximately 13 weeks for females and 14 weeks for males - Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Vehicle control
- Dose / conc.:
- 12.5 mg/kg bw/day
- Dose / conc.:
- 25 mg/kg bw/day
- Dose / conc.:
- 50 mg/kg bw/day
- Dose / conc.:
- 100 mg/kg bw/day
- No. of animals per sex per dose:
- 8 animals/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Results from two 90-day dermal studies.
- Rationale for animal assignment (if not random):random
- Other: none - Positive control:
- none; not required for this study type
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice per day
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:at least weekly during acclimation period; First 5 days of dosage: prior to dosage and at approx. hourly intervals for the first 4 hours after dosage administration, and at the end of day; From day 6 of treatment: prior to dosage administration, 1-2hrs after dosage administration and at the end of the day; Day of sacrifice: once.; Postdosage periods: once daily.
BODY WEIGHT: Yes
- Time schedule for examinations: Acclimation period: at least weekly; Dosage period: daily; On sacrifice day: Once
FOOD CONSUMPTION: Yes; at least weekly for males; For females, at least weekly during acclimation and precohabitation periods, on gestation days 0, 7, 8, 9, 10, 14, 18, 21 and 25, and on postpartum days 1 and 5.
WATER CONSUMPTION No
OTHER: Rats were evaluated for adverse clinical signs observed during parturition, duration of gestation (from day 0 of gestation till the day the first pup was observed), litter sizes (all pups delivered) and pup viability at birth. Maternal behaviour was evaluated on pospartum days 1 and 5. - Oestrous cyclicity (parental animals):
- By examination of vaginal cytology for 14 days before cohabitation, and then until spermatozoa were observed in a smear of the vaginal contents and/or a copulatory plug was observed in situ during the cohabitation period.
- Sperm parameters (parental animals):
- Epididymides, prostate, seminal vesicles and testes were weighed and microscopically evaluated.
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: no
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, weight gain, clinical observations
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead. Those that died before examination of the litter for pup viability were evaluated by immersing their lungs in water. Pups with lungs that sunk were identified as stillborn. Pups with lungs that floated were identified as liveborn and to have died shortly after birth. Pups that died before scheduled termination on days 2-5 postpartum were preserved in Bouin's solution for possible future evaluation except when precluded by autolysis. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals after completion of cohabitation period on day 46 of treatment.
- Maternal animals: All surviving animals on postpartum day 5, day study 46 or day gestation 25.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera. Uteri of apparently nonpregnant rats were examined, while being pressed between glass plates, to confirm the absence of implantation sites, and were retained in 10% NBF.
HISTOPATHOLOGY / ORGAN WEIGHTS
The following tissues were prepared for microscopic examination and weighed: Epididymides, gross lesions/masses (only histology), ovaries, prostate, seminal vesicles, testes, uterus with cervix. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring at 4 days of age (postpartum day 5).
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including a single cross-section of the head at the level of the frontal-parietal suture and examination of the cross-sectioned brain for apparent hydrocephaly. - Statistics:
- Averages and percentages calculated
- Reproductive indices:
- % rats that mated; Fertility index (number of pregnancies/number of rats that mated); % rats mated with female on days 1-7; % Pregnant rats among those cohabited
- Offspring viability indices:
- % delivered litters; number implantation sites per delivered litter; % dams with stillborn pups; Gestation index (number of dams with one or more liveborn pups/number of pregnant rats); % dams with all pups dying days 1-5 postpartum; Viability index (number of live pups on day 5 postpartum/ number of liveborn pups on day 1 postpartum; Surviving pups/litter on day 1 and on day 5; % male pups per number of pups sexed on day 1 and 5; Live litter size at weighing on day 1 and 5; Pup weight/litter on day 1 and 5;
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- maternal body weight gains in the 100 mg/kg/day group were reduced on days 1-5 of lactation, in comparison with control group
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- maternal food consumption in the 100 mg/kg/day group was reduced on days 1-5 of lactation, in comparison with control group
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No treatment related effects observed
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No treatment related effects observed.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Thie highest dose level of 100 mg/kg bw/d was found to cause mild maternal toxicity and no effects on reproduction or prenatal development.
- Executive summary:
In an OECD 421 screening study, groups of male and female rats were administered hexylcinnamaldehyde in corn oil by gavage daily for 14 days before mating. The administered doses were 0, 12.5, 25, 50 and 100 mg/kg bw/d. The cohabitation lasted 7 days. The day when the presence of spermatozoa and/or vaginal plug was detected was assigned as Gestation Day 0. Dams were allowed to deliver their litters. Animals continued to be dosed through cohabitation and continuing through the day before sacrifice. For males this was on Day 45 of the study, and for females was on postpartum day 5. F1 generation were sacrificed on Lactation Day 5. The following parameters were evaluated: viability, clinical observations, body weights, feed weights, mating and fertility, delivery and litter observations, organ weights, necropsy observations and histopathology. The only effects observed were a reduction of maternal body weight gain and feed consumption in the 100 mg/kg bw/d group on days 1 and 5 of lactation in comparison to the vehicle control group. The NOAEL for reproduction and developmental toxicity was 100 mg/kg bw/d, in the absence of any treatment-related findings at the highest dose level.
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2009-2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
Read-across is proposed for this endpoint, using data available for the analogue substance hexyl cinnamic aldehyde. A detailed justification for the proposed read-across approach is attached. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc.
- Age at study initiation: (P) Males: 85 days; Females: 79 days
- Weight at study initiation: (P) Males: 316-342 g; Females: 201-230 g
- Fasting period before study:no data
- Housing: P generation individually housed in steel wire-bottomed cages except during cohabitation and postpartum periods. From day 20 of presumed gestation female rats were housed individually in nesting boxes. Each dam and delivered litter were housed in a common nesting box during postpartum.
- Diet (e.g. ad libitum):ad libitum, Certified Rodent Diet #5002 (PMI Nutrition International)
- Water (e.g. ad libitum):ad libitum, mains sourced and filtered by reverse osmosis.
- Acclimation period:13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-26
- Humidity (%):30-70
- Air changes (per hr):at least 10
- Photoperiod (hrs dark / hrs light):12/12
IN-LIFE DATES: From: 17 Aug 2009 To: 2 Oct 2009 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Suspensions of test substance were prepared daily, stored at room temperature and protected from light.
VEHICLE
- Justification for use and choice of vehicle (if other than water): no data
- Concentration in vehicle: 3.125, 6.25, 12.5, 25mg/ml
- Amount of vehicle (if gavage): 4ml/kg
- Lot/batch no. (if required):J-145
- Purity:no data - Details on mating procedure:
- - M/F ratio per cage: 1
- Length of cohabitation: 7 days
- Proof of pregnancy: vaginal plug and/or sperm in vaginal smear referred to as day 0 of pregnancy
- After 7 days of not mated females will be considered to be at day 0 of presumed gestation
- After successful mating each pregnant female was caged individually. Also those female rats in presumed gestation.
- Any other deviations from standard protocol: none - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- by HPLC-UV, validated internal method.
- Duration of treatment / exposure:
- Male rats: total 45 days - from 14days before cohabitation, through cohabitation (7 days) and continuing through the day before sacrifice after completion of the dosage period.
Female rats: total 44 or 45 days - from 14 days before cohabitation, through cohabitation (7 days), and continuing through the day before sacrifice on postpartum day 5, or study day 46 (for rats that did not become pregnant) or gestation day 25 (for rats that did not deliver). Dams with no surviving pups were sacrificed on postpartum day 1.
Pups were not administered the test substance directly but may have been exposed in utero or via maternal milk. - Frequency of treatment:
- Once daily. Dosage volume was adjusted daily on the basis of individual body weights recorded before administration.
- Details on study schedule:
- - No selection of F1 parental animals took place
- Age at mating of the mated animals in the study: approximately 13 weeks for females and 14 weeks for males - Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Vehicle control
- Dose / conc.:
- 12.5 mg/kg bw/day
- Dose / conc.:
- 25 mg/kg bw/day
- Dose / conc.:
- 50 mg/kg bw/day
- Dose / conc.:
- 100 mg/kg bw/day
- No. of animals per sex per dose:
- 8 animals/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Results from two 90-day dermal studies.
- Rationale for animal assignment (if not random):random
- Other: none - Positive control:
- none; not required for this study type
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice per day
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:at least weekly during acclimation period; First 5 days of dosage: prior to dosage and at approx. hourly intervals for the first 4 hours after dosage administration, and at the end of day; From day 6 of treatment: prior to dosage administration, 1-2hrs after dosage administration and at the end of the day; Day of sacrifice: once.; Postdosage periods: once daily.
BODY WEIGHT: Yes
- Time schedule for examinations: Acclimation period: at least weekly; Dosage period: daily; On sacrifice day: Once
FOOD CONSUMPTION: Yes; at least weekly for males; For females, at least weekly during acclimation and precohabitation periods, on gestation days 0, 7, 8, 9, 10, 14, 18, 21 and 25, and on postpartum days 1 and 5.
WATER CONSUMPTION No
OTHER: Rats were evaluated for adverse clinical signs observed during parturition, duration of gestation (from day 0 of gestation till the day the first pup was observed), litter sizes (all pups delivered) and pup viability at birth. Maternal behaviour was evaluated on pospartum days 1 and 5. - Oestrous cyclicity (parental animals):
- By examination of vaginal cytology for 14 days before cohabitation, and then until spermatozoa were observed in a smear of the vaginal contents and/or a copulatory plug was observed in situ during the cohabitation period.
- Sperm parameters (parental animals):
- Epididymides, prostate, seminal vesicles and testes were weighed and microscopically evaluated.
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: no
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, weight gain, clinical observations
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead. Those that died before examination of the litter for pup viability were evaluated by immersing their lungs in water. Pups with lungs that sunk were identified as stillborn. Pups with lungs that floated were identified as liveborn and to have died shortly after birth. Pups that died before scheduled termination on days 2-5 postpartum were preserved in Bouin's solution for possible future evaluation except when precluded by autolysis. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals after completion of cohabitation period on day 46 of treatment.
- Maternal animals: All surviving animals on postpartum day 5, day study 46 or day gestation 25.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera. Uteri of apparently nonpregnant rats were examined, while being pressed between glass plates, to confirm the absence of implantation sites, and were retained in 10% NBF.
HISTOPATHOLOGY / ORGAN WEIGHTS
The following tissues were prepared for microscopic examination and weighed: Epididymides, gross lesions/masses (only histology), ovaries, prostate, seminal vesicles, testes, uterus with cervix. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring at 4 days of age (postpartum day 5).
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including a single cross-section of the head at the level of the frontal-parietal suture and examination of the cross-sectioned brain for apparent hydrocephaly. - Statistics:
- Averages and percentages calculated
- Reproductive indices:
- % rats that mated; Fertility index (number of pregnancies/number of rats that mated); % rats mated with female on days 1-7; % Pregnant rats among those cohabited
- Offspring viability indices:
- % delivered litters; number implantation sites per delivered litter; % dams with stillborn pups; Gestation index (number of dams with one or more liveborn pups/number of pregnant rats); % dams with all pups dying days 1-5 postpartum; Viability index (number of live pups on day 5 postpartum/ number of liveborn pups on day 1 postpartum; Surviving pups/litter on day 1 and on day 5; % male pups per number of pups sexed on day 1 and 5; Live litter size at weighing on day 1 and 5; Pup weight/litter on day 1 and 5;
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- maternal body weight gains in the 100 mg/kg/day group were reduced on days 1-5 of lactation, in comparison with control group
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- maternal food consumption in the 100 mg/kg/day group was reduced on days 1-5 of lactation, in comparison with control group
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No treatment related effects observed
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No treatment related effects observed.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Thie highest dose level of 100 mg/kg bw/d was found to cause mild maternal toxicity and no effects on reproduction or prenatal development.
- Executive summary:
In an OECD 421 screening study, groups of male and female rats were administered hexylcinnamaldehyde in corn oil by gavage daily for 14 days before mating. The administered doses were 0, 12.5, 25, 50 and 100 mg/kg bw/d. The cohabitation lasted 7 days. The day when the presence of spermatozoa and/or vaginal plug was detected was assigned as Gestation Day 0. Dams were allowed to deliver their litters. Animals continued to be dosed through cohabitation and continuing through the day before sacrifice. For males this was on Day 45 of the study, and for females was on postpartum day 5. F1 generation were sacrificed on Lactation Day 5. The following parameters were evaluated: viability, clinical observations, body weights, feed weights, mating and fertility, delivery and litter observations, organ weights, necropsy observations and histopathology. The only effects observed were a reduction of maternal body weight gain and feed consumption in the 100 mg/kg bw/d group on days 1 and 5 of lactation in comparison to the vehicle control group. The NOAEL for reproduction and developmental toxicity was 100 mg/kg bw/d, in the absence of any treatment-related findings at the highest dose level.
Referenceopen allclose all
There were no mortalities. All clinical observations were considered unrelated to treatment.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
Males: body weights and body weight gains, and absolute (g/day) and relative (g/kg/day) feed consumption were generally comparable among the dosage groups.
Females:
Precohabitation - body weights increased during second week compared to control group and overall for the entire premating period (14% greater than controls). These increases were not considered adverse since they didn't persist and there was not corresponding effect on feed consumption. Gestation - Body weights and feed consumption were unaffected by treatment.
Lactation - maternal body weight gains in the 100mg/kg/day were reduced on days 1-5 of lactation, in comparison with control group. Corresponding to reduced body weight gains during the lactation period, feed consumption values in the 100mg/kg/day were reduced in comparison to the vehicle group.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
The number of estrous stages per 14 days was comparable among the five dosage groups during the precohabitation period.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
All mating and fertility parameters were unaffected at all dosages (fertility index, rats with confirmed mating dates during cohabitation and number of pregnancies per number of rats in cohabitation).
There was an apparent increase in the average number of days to mating and a reduction in % of rats that mated that occurred in the highest dose group. This was attributed to two male rats that did not mate with their cohort rats. These effects were not attributed to treatment for the following reasons: 1) there was no apparent effect on male or female reproductive organ weights; 2) the remaining rats in the 100mg/kg/day dosage group (N=6) mated and had viable litters; 3) there were not apparent effects on natural delivery in this dosage group; and 4) the average value (3.4+/- 2.3 days) was within the historical range of the Testing Facility.
ORGAN WEIGHTS (PARENTAL ANIMALS)
The weights of the epididymides, testes, seminal vesicles (with and without fluid) and prostate and the ratios of these organ weights to terminal body weight were unaffected.
GROSS PATHOLOGY (PARENTAL ANIMALS)
There were no treatment-related gross lesions at any dosage level tested.
HISTOPATHOLOGY (PARENTAL ANIMALS)
None of the microscopic findings that occurred were considered related to the test substance. They were all considered to be incidental or spontaneous changes.
No treatment related clinical observations occurred or tretment related necropsy observations. All pups that died early or survived to scheduled sacrificed appeared normal at necropsy.
Dose formulation analysis showed they were within the acceptable limits.
There were no mortalities. All clinical observations were considered unrelated to treatment.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
Males: body weights and body weight gains, and absolute (g/day) and relative (g/kg/day) feed consumption were generally comparable among the dosage groups.
Females:
Precohabitation - body weights increased during second week compared to control group and overall for the entire premating period (14% greater than controls). These increases were not considered adverse since they didn't persist and there was not corresponding effect on feed consumption. Gestation - Body weights and feed consumption were unaffected by treatment.
Lactation - maternal body weight gains in the 100mg/kg/day were reduced on days 1-5 of lactation, in comparison with control group. Corresponding to reduced body weight gains during the lactation period, feed consumption values in the 100mg/kg/day were reduced in comparison to the vehicle group.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
The number of estrous stages per 14 days was comparable among the five dosage groups during the precohabitation period.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
All mating and fertility parameters were unaffected at all dosages (fertility index, rats with confirmed mating dates during cohabitation and number of pregnancies per number of rats in cohabitation).
There was an apparent increase in the average number of days to mating and a reduction in % of rats that mated that occurred in the highest dose group. This was attributed to two male rats that did not mate with their cohort rats. These effects were not attributed to treatment for the following reasons: 1) there was no apparent effect on male or female reproductive organ weights; 2) the remaining rats in the 100mg/kg/day dosage group (N=6) mated and had viable litters; 3) there were not apparent effects on natural delivery in this dosage group; and 4) the average value (3.4+/- 2.3 days) was within the historical range of the Testing Facility.
ORGAN WEIGHTS (PARENTAL ANIMALS)
The weights of the epididymides, testes, seminal vesicles (with and without fluid) and prostate and the ratios of these organ weights to terminal body weight were unaffected.
GROSS PATHOLOGY (PARENTAL ANIMALS)
There were no treatment-related gross lesions at any dosage level tested.
HISTOPATHOLOGY (PARENTAL ANIMALS)
None of the microscopic findings that occurred were considered related to the test substance. They were all considered to be incidental or spontaneous changes.
No treatment related clinical observations occurred or tretment related necropsy observations. All pups that died early or survived to scheduled sacrificed appeared normal at necropsy.
Dose formulation analysis showed they were within the acceptable limits.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available (further information necessary)
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Adequate information for classification without conducting further studies.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The 14-day repeated-dose toxicity study showed marked toxicity (both systemic and local effects) at 1000 mg/kg bw/d. Furthermore, the findings observed in the reproduction screening test (similar to OECD TG 421) showed that the highest dose level of 100 mg/kg bw/day can be considered as the maximum tolerated dose (MTD) for the dams.
Although the exposure duration of this study may not be sufficient to detect all effects on the spermatogenic cycle, it was assumed that in practice the 2-week exposure period would be sufficient to detect the majority of testicular toxicants.
The absence of adverse effects on reproduction or on reproductive organs up to 100 mg/kg bw/d HCA (considered as MTD in this study) in the reproduction screening test together with the toxicity of HCA observed at higher doses in the 14-day repeated dose toxicity study were sufficient to meet the information needs for non-classification for toxicity to reproduction. It was concluded that the conduct of a 2 -generation reproductive toxicity study should be waived on the basis of this information since the study would not contribute significant additional information.
Supplementary evidence to support this conclusion, comes from a multi-generation database on 50 substances which was recently analysed for second generation parental (P1) / offspring (F2) compared to parental (P0) and first generation offspring (F1) with regard to type of effects as well as incidence, magnitude and severity, at different dose levels. It was demonstrated that P1/F2 generation findings did not play a crucial role in the classification decisions for any substances except one which already provided abundant alerts for endocrine activity and developmental neurotoxicity. The classification of cinnamic aldehydes including hexyl and amyl forms would not be changed by conducting further reproductive/fertility investigations
Short description of key information:
The 14-day repeated-dose toxicity studies showed marked toxicity (both systemic and local effects) at 1000 mg/kg bw/d.
Furthermore, the findings observed in the reproduction screening test (similar to OECD TG 421) showed that the highest dose level of 100 mg/kg bw/day can be considered as the maximum tolerated dose (MTD) for the dams.
Justification for selection of Effect on fertility via oral route:
A position paper was prepared to justify waiving the multi-generation reproductive toxicity study. The position paper is based on findings from a single generation study with hexylcinnamic aldehyde. The 14-day repeated-dose toxicity studies showed marked toxicity (both systemic and local effects) at 1000 mg/kg bw/d.
Furthermore, the findings observed in the reproduction screening test (similar to OECD TG 421) showed that the highest dose level of 100 mg/kg bw/day can be considered as the maximum tolerated dose (MTD) for the dams.
Effects on developmental toxicity
Description of key information
OECD 414 (2019): No Observed Adverse Effect Level (NOAEL) of 60 mg/kg bw/day for developmental toxicity.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 December 2018 - April 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- The study was conducted to according to GLP and followed international guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 2018
- Deviations:
- yes
- Remarks:
- The observation for clinical signs was delayed by approximately 40 minutes.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Tennants Fine Chemicals Ltd, Batch no;51757 / 45562
- Expiration date of the lot/batch:15th October 2020
- Purity test date: 98.43%
RADIOLABELLING INFORMATION (if applicable)
- Radiochemical purity: N/A
- Specific activity: N/A
- Locations of the label: N/A
- Expiration date of radiochemical substance: N/A
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: +15 to +25ºC purged with nitrogen
- Stability of formulation under test conditions: stable - confirmed at 0.8 and 250 mg/mL.
- Solubility and stability of the test substance in the diet: N/A
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: N/A
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Based on results of validation study (Study No. G17456), test item formulations prepared at 0.8 and 250 mg/mL in the vehicle (Corn oil) were stable and resuspendable in the vehicle for 48 hours when stored at room temperature at both the concentrations.
- Preliminary purification step (if any): N/A
- Final dilution of a dissolved solid, stock liquid or gel: N/A
- Final preparation of a solid: N/A
FORM AS APPLIED IN THE TEST (if different from that of starting material) N/A
OTHER SPECIFICS: N/A - Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- . TEST ANIMALS
- Source: Liveon Biolabs Pvt. Ltd, Plot No.46 and 47, Water Tank Road, II Phase, KIADB Industrial Area, Antharasanahalli Kasaba Hobli, Tumkur District, Pin-572 106, Karnataka, India
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 7 months
- Weight at study initiation: Females: 3.207 - 3.244 kg.
- Fasting period before study: no
- Housing: The rabbits were housed individually, except during cohabitation, when the females rabbits were cohabited with the males in 1:1 ratio in rabbit cages (approximate size: Length 65 cm x Width 65 cm x Height 45 cm) with shallow cage body and facilities for providing pelleted food (Stainless steel feed hopper) and drinking water in bottle fitted with sipper tube. The waste collection tray was changed daily (except on Sundays and public holidays). .
- Water (e.g. ad libitum): ad libitum in polycarbonate bottles with stainless steel sipper tubes
- Acclimation period: 5 days prior to the commencement of treatment.
DETAILS OF FOOD AND WATER QUALITY: Rabbit feed manufactured by Special Diets Services, P.O Box 705, Witham, Essex, CM8 3AD, England (Batch No.3439) was provided ad libitum in stainless steel feed hoppers to rabbitse. Deep bore-well water passed through activated charcoal filter and exposed to UV rays in Aquaguard water filter-cum-purifier (Eureka Forbes Ltd, Mumbai, India) was provided ad libitum in polycarbonate bottles with stainless steel sipper tubes to rabbits.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 21 ºC
- Humidity (%): 64 to 65 %
- Air changes (per hr): 12 - 15 air changes/hour.
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark cycle.
IN-LIFE DATES: From: 29 December 2018 To 12 February 2019 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dose formulations were prepared prior to treatment and used within the stability period of 48 hours.
VEHICLE - Justification for use and choice of vehicle (if other than water): Cornoil
- Concentration in vehicle: not specified
- Amount of vehicle (if gavage): 1 mL/kg body weight
- Lot/batch no. (if required): MKCF8882
- Purity: not stated - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The method for determination of the test item concentration in dose formulation with the vehicle (corn oil) was successfully validated for specificity, linearity and range, LOD, LOQ, accuracy and precision at a claimed concentration of 0.833 and 250.50 mg/mL. The test item was observed to form homogenous suspension in the vehicle and found to be stable and re-suspendable in the vehicle at 0.833 and 250.50 mg/mL up to 48 hours, when stored at room temperature
- Details on mating procedure:
- During the mating period, females were cohabited randomly with males in a 1:1 ratio. in rabbit cages (approximate size: Length 65 cm x Width 65 cm x Height 45 cm) with shallow cage body and facilities for providing pelleted food (Stainless steel feed hopper) and drinking water in bottle fitted with sipper tube. The waste collection tray was changed daily (except on Sundays and public holidays). After confirmation of mating by visual examination, the Gestation Day 0 (GD 0) was recorded for each individual rabbit.
- Duration of treatment / exposure:
- GD 6 to GD 28
- Frequency of treatment:
- Daily
- Duration of test:
- 23 days
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Vehicle Control
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- Remarks:
- Low dose
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Remarks:
- Mid dose
- Dose / conc.:
- 60 mg/kg bw/day (nominal)
- Remarks:
- High dose
- No. of animals per sex per dose:
- 23
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
A preliminary dose range finding study (DRF) in pregnant female New Zealand White rabbits was carried out using 6 rabbits per group with the test item by oral gavage at a dose volume of 2 mL/kg body weight at 50, 150 and 300 mg/kg bw/day along with the concurrent vehicle control.
Based on the findings, 0, 15, 30 and 60 mg/kg/day dose levels at a dose volume of 1 mL/kg body weight were selected for the definitive study.
- Rationale for animal assignment (if not random): N/A - Other:
The test item formulations or vehicle was administered daily by oral gavage approximately the same time each day (varying by ± 2 hours). The dosing was performed using a suction catheter attached to a plastic disposable syringe from GD 6 to GD 28 of presumed gestation. Dose formulation was administered at 1 mL/kg body weight, with actual volume administered based on the most recent body weight.Dose formulations were continuously stirred during dose administrations. The animals in the vehicle control (G1) group were handled and administered vehicle in an identical manner to the treatment groups. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Not Stated
- Time schedule:
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: All rabbits were observed for morbidity and mortality twice daily, i.e. once in the morning and once in the afternoon. Rabbits were observed for clinical signs during the treatment period of the study: pre-dose and post dose (within 1- 2 hours of administration).
BODY WEIGHT: Yes - Time schedule for examinations: All the females included in the study (G1 to G4) were weighed on GD 0, 3, 6, 9, 12, 15, 18, 21, 24, 27 and 29.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
About 600 g of food (food input) was provided on GD 0. The left-over food was recorded and replenished to about 600 g on GD 3, 6, 9, 12, 15, 18, 21, 24 and 27. Prior to terminal sacrifice, left over food was recorded on GD 29 of presumed gestation.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not Stated
- Time schedule for examinations: Not Stated POST-MORTEM EXAMINATIONS: Yes - Sacrifice on gestation day # GD 29
- Organs examined: Yes, external and visceral organs
OTHER: The following data were recorded.
* Pregnancy status
* Gravid Uterine weight (from all rabbits subjected to caesarean section)
* Number of corpora lutea
* Number of implantation sites
* Number of early resorptions
* Number of late resorptions
* Gross evaluation of placenta - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Yes, gross evaluation of placenta, pregnancy status - Fetal examinations:
- - External examinations: Yes:
- Soft tissue examinations: Yes:
- Skeletal examinations: Yes:
- Head examinations: Yes:
- Other: The following litter data were recorded:
* Total number of fetuses
* Number of live fetuses
* Number of dead fetuses
* Individual fetal body weight
* Fetus sex - Statistics:
- The data on maternal body weight and food consumption, interval body weight changes, gravid uterine weight, body weight change corrected to gravid uterine weight were analyzed using Analysis of Variance (ANOVA) after testing for homogeneity for intra group variance using Levene’s test. Where intra group variances were heterogeneous, ANOVA was performed after suitable transformation of data. Dunnett’s pairwise comparison of the treated group means with the control group mean was performed, when the group differences were found significant.
Fetal weight for male and female was analyzed using Analysis of Covariance (ANCOVA) taking litter size as covariate for group.
Number of corpora lutea, number of implantations, early and late resorptions/deaths, pre-implantation and post-implantation loss, external, soft tissue and skeletal observations for variations were analyzed using Kruskal Wallis test for group comparison. Wilcoxon test pair wise comparisons of the treated groups with the control group was performed, when the group differences were significant.
The incidence of dams with and without resorptions was tested using Cochran Armitage trend test followed by Fisher’s exact test for group association.
Statistically significant differences (p<0.05) were designated as * - Indices:
- n/a
- Historical control data:
- Yes
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There was a total of four abortions observed – one at each dose group. viz, one each in vehicle control and at 15 mg/kg/day on GD 26, one at 30 mg/kg/day on GD 27 and one at 60 mg/kg/day on GD 23. Rabbits being sensitive animals, occurance of abortions are considered incidental.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The mean maternal body weights, body weight gain and adjusted body weights during the different periods of gestation (GD 0-6; GD 6-29; GD 0-29) of the treated rabbits were statistically comparable to the vehicle control group at all the doses tested.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Compared to the vehicle control group, there was no change in food consumption of rabbits dosed at 15 mg/kg/day. There was a significant decrease (23 to 33%) in food consumption during initial stage of gestation (GD 6-9) at 30 mg/kg/day. The significant reduction (21 to 33%) in food consumption was observed during GD 6-9, 9-12, 12-15, 18-21, 24-27, 27-29, 6-29 and 0-29 at 60 mg/kg/day.
The reduction in food consumption at 30 mg/kg/day was observed during initial stage and hence was not considered adverse as the food consumption during treatment period was comparable to control group. Also the reduction at 60 mg/kg/day was not of any toxicological significance as there was no concomittent reduction in maternal body weights. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no gross pathological findings in any of the treated groups
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Number of abortions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Incidental abortions were observed in each of the, vehicle control, low, mid and high dose groups. There was a total of four abortions observed – one at each dose group. viz, one each in vehicle control and at 15 mg/kg/day on GD 26, one at 30 mg/kg/day on GD 27 and one at 60 mg/kg/day on GD 23. Rabbits being sensitive animals, occurance of abortions are considered incidental.
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- Exposure to the Amyl Cinnamic Aldehyde up to 60 mg/kg bw/day caused no evident toxicity related to clinical signs, body weights, food consumption or gross necropsy findings at any of the doses tested except for one incidental abortion in all treatment groups including vehicle control. The maternal and litter data parameters were unaffected, fetal external, visceral and skeletal examination revealed no signs of teratogenicity up to the highest tested dose of 60 mg/kg/day.
In conclusion, based on the above findings, under the test conditions employed in the study, it was concluded that No - Observed - Effect Level (NOEL) for: Maternal toxicity and fetal developmental toxicity is 60 mg/kg/day. Therefore, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008 (CLP). - Executive summary:
OECD 414 - (2019): Amyl Cinnamic Aldehyde when administered daily by oral gavage during gestation days (GD) 6 to 28 to presumed pregnant New Zealand White rabbits. This study evaluated the maternal toxicity and adverse effects on development of the embryo and fetus in pregnant female rabbits. 92 mated female rabbits were assigned to four groups. Each group consisted of 23 mated rabbits (G1: vehicle control, G2: low dose, G3: mid dose and G4: high dose). Day 0 of gestation for each individual female rabbit in the study was considered as the day on which mating had occurred. Test item in vehicle (Corn oil) was administered at 0, 15, 30 and 60 mg/kg/day at the dose volume of 1mL/kg body weight. The control group received the vehicle only.
The data of maternal and litter parameters were analysed and presented only for pregnant rabbits at caesarean section. There were no clinical signs or mortalities observed at any of the doses tested during the study period. However, there was a total of four abortions observed – one at each dose group viz, one each in vehicle control and at 15 mg/kg/day on GD 26, one at 30 mg/kg/day on GD 27 and one at 60 mg/kg/day on GD 24. Rabbits being sensitive animals, occurance of abortions are considered incidental.
The mean maternal body weights, body weight gain and adjusted body weights during the different periods of gestation (GD 0-6; GD 6-29; GD 0-29) of the treated rabbits were statistically comparable to the vehicle control group at all the doses tested.
Compared to the vehicle control group, there was no change in food consumption of rabbits dosed at 15 mg/kg/day. There was a significant decrease (24%) in food consumption during initial stage of gestation (GD 6-9) at 30 mg/kg/day. The significant reduction (21 to 36%) in food consumption was observed during GD 6-9, 9-12, 12-15, 18-21, 24-27, 27-29, 6-29 and 0-29 at 60 mg/kg/day. The reduction in food consumption at 30 mg/kg/day was observed during initial stage and hence was not considered adverse as the food consumption during treatment period was comparable to control group. Also the reduction at 60 mg/kg/day was not of any toxicological significance as there was no concomittent reduction in maternal body weights.
The maternal parameters comprising of gravid uterine weight and mean number of corpora lutea, implantations, early and late resorptions, pre and post implantation loss and dams with resorptions were statistically comparable between the vehicle control and rabbits treated at 15, 30 and 60 mg/kg/day. Gross evaluation of placenta did not reveal any findings in any dams at any tested dose levels.
The litter parameters comprising total number of fetuses, mean fetal weight were comparable between the vehicle control group and rabbits treated at all the doses tested.
No test item related major abnormality was observed during external observation of the fetuses at any of the doses. Anomaly of umbilical hernia was observed in one fetus of a litter with 2 fetuses (RBa5031) at 60 mg/kg/day. This was considered as an incidental finding.
There were no test item related major visceral malformations observed in fetuses of dams treated up to 60 mg/kg/day. Anomalies such as gall bladder hypoplastic in vehicle and test item treated groups and hyperplastic gall bladder in control and high dose group, bilobed gall bladder in low dose group were observed. These findings were not considered adverse as these observations commonly occur in animals of this test model and the incidence of occurrence was consistent with concurrent or historical controls.
There were no test item related skeletal malformations observed in fetuses of dams treated up to 60 mg/kg/day. Variants and anomalies observed across vehicle and test item treated groups were comparable and are consistent with concurrent and historical data.
There were no gross pathological changes at any dose level. External and visceral and skeletal examination of fetuses revealed no signs of teratogenicity.
In conclusion, based on the above findings, under the test conditions employed in the study, it was concluded that No - Observed - Effect Level (NOEL) for: Maternal toxicity and fetal developmental toxicity is 60 mg/kg/day. Therefore, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008 (CLP).
criteria for classification according to Regulation (EC) No 1272/2008 (CLP). criteria for classification according to Regulation (EC) No 1272/2008 (CLP).
- Endpoint:
- developmental toxicity
- Remarks:
- Dose-range finding test
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 02 November 2018 to 26 February 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- Dose range finding test
- Deviations:
- no
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Liveon Biolabs Pvt. Ltd, Plot No. 46 & 47. Water Tank Road, II Phase, KIADB Industrial Area, Anthrarasanahalli Kasaba Hobli, Tumkur District, Pin-572-106, Karnataka, India
- Age at study initiation: 8-9 months
- Weight at study initiation:
Mean body weight of day 0 pregnant rabbits:
G1 - 3.440 +/- 0.19 kg
G2 - 3.422 +/- 0.20 kg
G3 - 3.475 +/- 0.24 kg
G4 - 3.460 +/- 0.24 kg
- Fasting period before study:
- Housing: The rabbits were housed individually (except during cohabitation when the female rabbits will be cohabited with males in 1:1 ratio) in rabbit cages (approx. size: Length 65 x Width 65 X Height 45 cm) with shallow cage body and perforated raised shelf and facilities for providing pelleted food (stainless steel feed hopper) and drinking water in bottle fitted with a sipper tube. The waste collection tray was changed daily (except on Sundays and general holidays).
- Diet (e.g. ad libitum): ad libitum (Rabbit feed manufactured by Special Diets Services, P.O BOX 705, Witham, Essex, CM8 3AD, England)
- Water (e.g. ad libitum): ad libitum (Deep bore-well water passed through activated charcoal filter and exposed to UV rays in Aquaguard water filter-cum-purifier manufactured by Eureka Forbes Ltd, Mumbai, India)
- Acclimation period: After physical examination for good health and suitability for the study, 35 female and 30 male rabbits were acclimatized for five days before initiation of mating. During the acclimatization period, all rabbits will be observed once daily.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 (± 3) °C
- Humidity (%): 30 – 70 %,
- Air changes (per hr): 12 - 15 air changes/hour
- Photoperiod (hrs dark / hrs light): 12:12 h light:dark
IN-LIFE DATES: From: To: 02 November 2018 to 06 December 2018 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): Dose formulations were prepared prior to treatment and used within the stability period of 48 hours.
- Mixing appropriate amounts with (Type of food): Based on the dose required quantities of the test item were weighed accurately (in the respective pre-calibrated beakers) and a small volume of vehicle was added and mixed thoroughly using a glass rod. The final volume was made up to the mark with the vehicle to get the required intended volume.
The homogeneity of the dose formulation during sampling/treatment was maintained by constant stirring using magnetic stirrer.
- Storage temperature of food: Not reported
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil
- Concentration in vehicle: 50 mg/kg bw/day = 25 mg/mL; 150 mg/kg bw/day = 75 mg/mL; 300 mg/kg bw/day = 150 mg/mL
- Amount of vehicle (if gavage): 2 mL/kg body weight
- Lot/batch no. (if required): MKCF8882
- Purity: not stated - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: Cohabitation
- If cohoused: Female rabbits were cohabited with males in 1:1 ratio; naïve males untreated with the test item were used for mating purpose only.
- M/F ratio per cage: 1:1
- Length of cohabitation: Not reported
- Further matings after two unsuccessful attempts: No
- Verification of same strain and source of both sexes: Not reported
- Proof of pregnancy: Not reported
- Any other deviations from standard protocol: N/A - Duration of treatment / exposure:
- From gestation day (GD) 6 to 28.
- Frequency of treatment:
- Daily
- Duration of test:
- 23 days
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Vehicle Control (G1)
- Dose / conc.:
- 50 mg/kg bw/day
- Remarks:
- (G2)
- Dose / conc.:
- 150 mg/kg bw/day
- Remarks:
- (G3)
- Dose / conc.:
- 300 mg/kg bw/day
- Remarks:
- (G4)
- No. of animals per sex per dose:
- 6
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on existing toxicity data on substance
- Rationale for animal assignment (if not random): Day 0 pregnant rabbits (GD 0 for each individual female rabbit in the study will be considered the day on which mating has occurred) obtained on each day were randomly distributed to different groups by body weight stratification method using ProvantisTM software.
- Other: N/A - Maternal examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: All the rabbits were observed twice daily for clinical signs during the in-life phase of the study, once prior to treatment and once after post dose and observed for morbidity and mortality twice daily.
BODY WEIGHT: Yes
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Days 3, 6, 9, 12, 15, 18, 21, 24 and 27 and food output on Day 29 of presumed gestation was recorded.
- The intermittent food consumption i.e. gestation Day 0–3, 3–6, 6–9, 9–12, 12–15, 15–18, 18–21, 21–24, 24–27 and 27 to 29 was calculated. Further, food consumption for pre-treatment (GD 0 to 6), treatment (GD 6 to 28) and for entire gestation period (GD 0 to 29) was calculated.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 29
- Organs examined: Gross necropsy, which involves an external observation and thoracic and abdominal viscera including uterine contents, was be performed on all animals in the study including dead, moribund and those sacrificed pre-term or at term (caesarean section). - Ovaries and uterine content:
- - Examination of uterine contents:
Caesarean section: The gravid uterus including cervix was excised, weighed and immediately examined. The following maternal data were recorded: Pregnancy status, Gravid uterine weight (only for females killed at termination, not obtained from animals found dead or sacrificed moribund during the study), Number of corpora lutea, Number of implantation sites, Number of early resorptions, Number of late resorptions, Gross evaluation of placenta. - Fetal examinations:
- - Fetal Data (Examination of Fetuses): The individual fetuses were removed sequentially, all the fetuses were identified by serial numbers. The fetuses were euthanized by sodium thiopentone injection.
The following litter data were recorded: Total number of fetuses, Number of live fetuses, Number of dead fetuses, Individual fetal body weight (g), Fetus sex. All the fetuses were also examined for external malformations. - Statistics:
- The data on maternal body weight, body weight change in interval, gravid uterine weight, and body weight change corrected to gravid uterine weight, maternal food consumption were analyzed using Analysis of Variance (ANOVA) after testing for homogeneity for intra group variance using Levene’s test. Where intra group variances are heterogeneous, ANOVA were performed after suitable transformation of data. Dunnett’s pairwise comparison of the treated group means with the control group mean were performed, when the group differences are found significant.
Fetal weight for male and female were analyzed using Analysis of Covariance (ANCOVA) taking litter size as covariate for group.
Number of corpora lutea, number of implantations, early and late resorptions, pre-implantation and post-implantation loss, external observations for variations were analyzed using Kruskal Wallis test for group comparison. Mann-Whitney pairwise comparison of the treated groups with the control group were performed, when the group differences are significant.
The incidence of with and without resorptions in dams were tested using Cochran Armitage trend test followed by Fisher’s exact test for group association.
Statistically significant differences (p<0.05), indicated by the aforementioned tests were designated. - Historical control data:
- Not reported
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- There was treatment related clinical signs at the tested doses of 150 and 300 mg/kg/day. At 50 mg/kg there were transient clinical signs of slight to severe salivation and nasal discharge in one rabbit (RBa4840) during (GD16 to 19) which recovered from GD 20 onwards. The remaining rabbits in this group were normal.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- At the dose of 150 mg/kg/day there were 2/6 mortalities and two rabbits were moribund sacrificed. Hence this group was terminated on GD 19 and the surviving two rabbits were euthanized. At the dose of 300 mg/kg/day there were 3/6 mortalities and one rabbit was moribund sacrificed. Hence this group was terminated on GD 12 and the surviving two rabbits were euthanized.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean body weights (134%) of rabbits at 50 mg/kg, was reduced during treatment period as compared to the control group.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The mean food consumption (17%) of rabbits at 50 mg/kg, was reduced during treatment period as compared to the control group.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not specified
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- no effects observed
- Details on maternal toxic effects:
- Mean or individual values of maternal parameters comprising of uterine weight, number of corpora lutea, implantations and early and late resorptions were comparable to the vehicle control group at the dose of 50 mg/kg/day. Gross evaluation of placenta revealed no findings.
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- not examined
- Visceral malformations:
- not examined
- Other effects:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- The litter data parameters comprising of total number of fetuses, number of live fetuses, male and female fetal weights were statistically comparable to vehicle control group.
No abnormality was noticed on external observations of fetuses at any of the doses tested. - Conclusions:
- Based on the results of the dose range finding study the following doses are selected for the definitive study:
Vehicle control - 0 mg/kg/day
Low dose - 15 mg/kg/day
Mid dose - 30 mg/kg/day
High dose - 60 mg/kg/day - Executive summary:
The objective of this dose range finding study was to select the doses for the definitive prenatal developmental toxicity study in New Zealand white rabbits. This study evaluated the maternal and developmental toxicity of the test item Amyl Cinnamic Aldehyde when administered orally to pregnant New Zealand white rabbits from gestation days (GD) 6 to 28.
The test item, Amyl cinnamic aldehyde was suspended in vehicle (corn oil) and administered orally from gestation Day (GD) 6 to 28 at the doses of 50 (G2), 150 (G3) and 300 (G4) mg/kg/day, along with the concurrent vehicle control (G1). The animals in the vehicle control group were handled in an identical manner as in the treatment groups and treated with vehicle.
In this dose range finding study, 24 mated female rabbits were assigned to four groups. Each group consisted of 6 mated rabbits (G1: vehicle control, G2: low dose, G3: mid dose and G4: high dose). Day 0 of gestation for each individual female rabbit in the study was considered as the day on which mating had occurred.
All the rabbits were observed twice daily for clinical signs during the in-life phase of the study, once prior to treatment and once after post dose and observed for morbidity and mortality twice daily. Body weights changes and food consumption was recorded. Caesarean section was performed for all the rabbits on GD 29 and dams were examined for gross pathological changes. The uterus was removed by laparotomy, weighed and the contents were examined for number of implantation sites, early and late resorptions and number of fetuses. The number of corpora lutea in ovaries was counted. All the fetuses were sexed, weighed and examined for external malformations.
The results from the study are as follows:
- There was treatment related clinical signs at the tested doses of 150 and 300 mg/kg/day. At the dose of 150 mg/kg/day there were 2/6 mortalities and two rabbits were moribund sacrificed. Hence this group was terminated on GD 19 and the surviving two rabbits were euthanized. At the dose of 300 mg/kg/day there were 3/6 mortalities and one rabbit was moribund sacrificed. Hence this group was terminated on GD 12 and the surviving two rabbits were euthanized.
- At 50 mg/kg there were transient clinical signs of slight to severe salivation and nasal discharge in one rabbit (RBa4840) during (GD16 to 19) which recovered from GD 20 onwards. The remaining rabbits in this group were normal.
- Body weight and food consumption: The mean body weights (134%) and food consumption (17%) of rabbits at 50 mg/kg, were reduced during treatment period as compared to the control group.
- Mean or individual values of maternal parameters comprising of uterine weight, number of corpora lutea, implantations and early and late resorptions were comparable to the vehicle control group at the dose of 50 mg/kg/day. Gross evaluation of placenta revealed no findings.
- The litter data parameters comprising of total number of fetuses, number of live fetuses, male and female fetal weights were statistically comparable to vehicle control group.
- No abnormality was noticed on external observations of fetuses at any of the doses tested.
Based on the results of the dose range finding study the following doses are selected for the definitive study:
Vehicle control - 0 mg/kg/day
Low dose - 15 mg/kg/day
Mid dose - 30 mg/kg/day
High dose - 60 mg/kg/day
Referenceopen allclose all
Table 2. Summarized Details of Necropsy
Parameters |
GD 6 to 28 (total 23 days) |
||||
Group No. & |
G1 |
G2 |
G3 |
G4 |
|
Dose (mg/kg/day) |
0 |
15 |
30 |
60 |
|
Total No. of rabbits / group |
23 |
23 |
23 |
23 |
|
Caesarean section (day of presumed gestation) |
29 |
||||
Number of rabbits aborted |
1 |
1 |
1 |
1 |
|
Number of rabbits sacrificed at caesarean section |
22 |
22 |
22 |
22 |
|
Number of rabbits non-pregnant at caesarean section |
1 |
3 |
2 |
2 |
|
Number of pregnant rabbits examined at caesarean section. |
21 |
19 |
20 |
20 |
|
Number of litters examined |
21 |
19 |
20 |
20 |
|
Total number of fetuses |
123 |
110 |
125 |
100 |
|
Number fetuses evaluated |
|||||
External, visceral and skeletal |
123 |
110 |
125 |
100 |
|
Number of fetus for decapitation |
57 |
51 |
57 |
45 |
|
Number of Entire fetuses |
66 |
59 |
68 |
55 |
Table 3. Summary of Clinical Signs and Mortality
Observation from Day 0- 29 |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
|
Normal |
23 |
23 |
23 |
23 |
Killed - humane |
1 |
1 |
1 |
1 |
Killed – terminal kill |
22 |
22 |
22 |
22 |
Abortion |
1 |
1 |
1 |
1 |
Table 4. Mean Maternal Body Weight of Pregnant Rabbits
Day(s) Relative to Mating |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
|
0 |
3.1839 |
3.2551 |
3.2157 |
3.1727 |
3 |
3.2278 |
3.2565 |
3.2214 |
3.1932 |
6 |
3.2397 |
3.2609 |
3.2450 |
3.2031 |
9 |
3.2364 |
3.2367 |
3.2246 |
3.1645 |
12 |
3.2203 |
3.2613 |
3.2137 |
3.1712 |
15 |
3.2463 |
3.2613 |
3.2394 |
3.1870 |
18 |
3.2881 |
3.2702 |
3.2400 |
3.2124 |
21 |
3.2652 |
3.2697 |
3.2312 |
3.2279 |
24 |
3.2688 |
3.2923 |
3.2361 |
3.2464 |
27 |
3.2667 |
3.2967 |
3.2399 |
3.2464 |
29 |
3.2898 |
3.3183 |
3.2701 |
3.2703 |
Table 5. Mean Maternal Body Weight Gain of Pregnant Rabbits
Day(s) Relative to Mating |
G1 |
G2 |
G3 |
G4 |
|
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
||
Absolute Weight Gain (kg) |
0-3[a] |
0.0604 |
0.0655 |
0.0461 |
0.0577 |
3-6[a] |
0.0120 |
0.0044 |
0.0236 |
0.0577 |
|
6®9[a] |
-0.0033 |
-0.0243 |
-0.0204 |
-0.0386 |
|
9-12[a] |
-0.0161 |
0.0246 |
-0.0109 |
0.0386 |
|
12-15[a] |
0.0260 |
0.0008 |
0.0258 |
0.0159 |
|
15-18[a] |
0.0418 |
0.0081 |
0.0005 |
0.0253 |
|
18-21[a] |
-0.0229 |
-0.0005 |
-0.0088 |
0.01155 |
|
21-24[a] |
0.0036 |
0.0226 |
0.0049 |
0.0185 |
|
24-27[a] |
-0.0021 |
0.0044 |
0.0038 |
0.0063 |
|
27-29[a] |
0.0231 |
0.0216 |
0.0302 |
0.0176 |
|
Absolute Weight Gain (kg) |
0-6[a] |
0.0559 |
0.0058 |
0.0293 |
0.0304 |
6-29[a] |
0.0501 |
0.0573 |
0.0251 |
0.0672 |
|
0-29[a] |
0.1060 |
0.0632 |
0.0544 |
0.0976 |
|
Adjusted Bodyweight (kg) |
[a] |
2.9490 |
2.9851 |
2.9145 |
2.9708 |
Adjusted Weight Gain (kg) |
[a] |
-0.2908 |
-0.2759 |
-0.3304 |
-0.2323 |
Table 6. Summary of Total Food Consumption of Pregnant Rabbits
Day(s) Relative to Mating |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
|
0-3 |
352 |
339.12 |
325.11 |
339.43 |
3-6 |
359.95 |
343.88 |
363.06 |
349.58 |
6-9 |
343.10 |
284.01 |
261.62* |
219.70* |
9-12 |
313.12 |
301.31 |
267.23 |
209.51* |
12-15 |
289.60 |
286.43 |
253.20 |
195.73* |
15-18 |
277.97 |
242.42 |
241.84 |
222.53 |
18 -21 |
269.25 |
269.20 |
254.87 |
212.28* |
21-24 |
244.97 |
236.44 |
214.13 |
210.16 |
24 - 27 |
223.53 |
250.10 |
194.14 |
173.13* |
27- 29 |
183.45 |
193.56 |
176.08 |
130.10* |
0 - 3[a] |
0.0604 |
0.0655 |
0.0461 |
0.0577 |
Anova & Dunnett(Log): * = p < 0.05
Table 7. Mean Food Consumption of Pregnant Rabbits
Day(s) Relative to Mating |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
|
0 - 3 |
117.49 |
113.04 |
108.37 |
113.14 |
3 - 6 |
119.98 |
114.63 |
121.02 |
116.53 |
6 - 9 |
114.37 |
94.67 |
87.20* |
73.23* |
9 - 12 |
104.37 |
100.44 |
89.08 |
69.84* |
12 -15 |
96.53 |
95.48 |
84.40 |
65.24* |
15 - 18 |
92.66 |
80.81 |
80.61 |
74.18 |
18 - 21 |
89.75 |
89.73 |
84.96 |
70.76* |
21 - 24 |
81.66 |
78.81 |
71.38 |
70.13 |
24 - 27 |
74.51 |
83.37 |
64.71 |
57.71* |
27 - 29 |
74.51 |
83.37 |
88.04 |
65.05* |
0 - 6 |
118.74 |
113.83 |
114.69 |
114.83 |
6 - 29 |
93.26 |
89.72 |
81.00* |
68.41* |
0 - 29 |
98.53 |
94.71 |
87.97 |
78.01* |
Anova & Dunnett(Log): * = p < 0.05
Table 8. Summary of Gross Necropsy Findings
Parameter |
Group No. & |
G1 |
G2 |
G3 |
G4 |
Dose (mg/kg/day) |
0 |
15 |
30 |
60 |
|
Total No. of rabbits / group |
23 |
23 |
23 |
23 |
|
Number of dead during treatment |
0 |
0 |
0 |
0 |
|
Number of moribund sacrifice |
0 |
0 |
0 |
0 |
|
Number of terminally sacrificed |
23 |
23 |
23 |
23 |
|
Number of examined for gross pathology. |
23 |
23 |
23 |
23 |
|
Number showing gross pathology |
Showing external pathology |
0 |
0 |
0 |
0 |
Showing visceral organ pathology |
0 |
0 |
0 |
0 |
Table 9. Summary of Maternal Data
Parameter |
GD |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
||
Pregnant |
GD29 |
21 |
19 |
20 |
20 |
Gravid Uterus (g) |
GD29 [a] |
340.9 |
333.2 |
355.6 |
299.5 |
Number of Corpora Lutea |
GD29 [k] |
7.4 |
7.7 |
8.3 |
7.5 |
No. of Implantation |
GD29 [k] |
6.3 |
6.2 |
6.7 |
5.9 |
No. of Early Deaths |
GD29 [k] |
0.1 |
0.3 |
0.2 |
0.8 |
No. of Late Deaths |
GD29 [k] |
0.3 |
0.2 |
0.2 |
0.4 |
Pre-implantation loss/Animal |
GD29 [k] |
1.14 |
1.53 |
1.65 |
1.60 |
% Pre-implantation loss |
GD29 [k] |
15.7 |
20.3 |
19.8 |
22.7 |
Post-implantation loss/Animal |
GD29 [k] |
0.43 |
0.42 |
0.40 |
0.90 |
% Post-implantation loss |
GD29 [k] |
6.2 |
6.5 |
5.5 |
17.7 |
Resorptions |
GD29 [f] |
21 |
19 |
20 |
20 |
[a] - Anova & Dunnett(Log)
[k] - Kruskal-Wallis & Wilcoxon
[f] - Chi-Squared & Fisher's Exact
Table 10. Summary of Litter Data
Parameter |
GD |
G1 |
G2 |
G3 |
G4 |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
||
Pregnant |
GD29 |
21 |
19 |
20 |
20 |
Total No. of Fetuses |
GD29 [a] |
5.9 |
5.8 |
6.3 |
5.0 |
Dead |
[a] |
0 |
0 |
0 |
0 |
Live Male |
sum |
67 |
58 |
59 |
50 |
Mean Fetal Weight (M) (g) |
GD29 [c] |
38.64 |
41.16 |
38.59 |
39.02 |
Live Female |
sum |
56 |
52 |
66 |
50 |
Mean Fetal Weight (F) (g) |
GD29 [c1] |
38.95 |
40.32 |
37.86 |
40.85 |
Live both |
sum |
123 |
110 |
125 |
100 |
Mean Fetal Weight (both) (g) |
GD29 [c2] |
38.96 |
40.37 |
38.34 |
40.09 |
[a] ‑ Anova & Dunnett(Log)
[c] ‑ Ancova/Anova & Dunnett; {Covariate(s): Number of Live Male Fetuses}
[c1] ‑ Ancova/Anova & Dunnett; Covariate(s): Number of Live Female Fetuses}
[c2] ‑ Ancova/Anova & Dunnett; {Covariate(s): Number of Live Fetuses}
Table 11. Summary of Fetal External, Visceral and Skeletal Observations
Group |
G1 |
G2 |
G3 |
G4 |
||
Dose |
0mg/kg/day |
15mg/kg/day |
30mg/kg/day |
60mg/kg/day |
||
No. of Fetuses examined |
123 |
110 |
125 |
100 |
||
No. of Litters Evaluated |
21 |
19 |
20 |
20 |
||
Exam Type: External |
|
|
|
|
||
Body
|
Umbilicus, Hernia - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
Exam Type: Fresh Visceral-Body Only |
|
|
|
|
||
Abdomen
|
Gallbladder, Hyperplastic - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
1(1.0)
1(5.0) |
Gallbladder, Bilobed gallbladder – Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
2(1.8)
2(10.5) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
Gallbladder, Hypoplastic - Anomaly |
Fetuses N(%)
Litters N(%) |
9(7.3)
5(23.8) |
8(7.3)
6(31.6) |
4(3.2)
3(15.0) |
1(1.0)
1(5.0) |
|
Exam Type: Skeletal - Body |
|
|
|
|
||
Hindlimbs: |
Metatarsal, middle phalange-4, Delayed skeletal ossification - Variation |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
2(3.9)
1(5.3) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
Lumbar vertebrae
|
8th lumbar centrum and arch, Extra - Anomaly |
Fetuses N(%)
Litters N(%) |
8(14.0)
4(19.0) |
3(5.9)
3(15.8) |
4(7.0)
4(20.0) |
4(8.9)
2(11.1) |
Ribs
|
14th rib, Left, Rudimentary - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
13th rib, Right, Accessory - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
2(3.9)
2(10.5) |
1(1.8)
1(5.0) |
1(2.2)
1(5.6) |
|
13th rib, Right, Rudimentary - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
1(2.0)
1(5.3) |
1(1.8)
1(5.0) |
1(2.2)
1(5.6) |
|
13th rib, Right, Rudimentary Float - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
1(2.0)
1(5.3) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
13th rib, Right, Extra - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
1(5.6) |
|
13th rib, Left, Accessory - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
13th rib, Left, Accessory Float - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
0(0.0)
2(10.5) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
13th rib, Left, Rudimentary - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
13th rib, Left, Rudimentary Float - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
1(2.0)
1(5.3) |
1(1.8)
1(5.0) |
0(0.0)
0(0.0) |
|
13th rib, Left, Extra - Anomaly |
Fetuses N(%)
Litters N(%) |
5(8.8)
3(14.3) |
3(5.9)
3(15.8) |
1(1.8)
1(5.0) |
1(2.2)
1(5.6) |
|
13th rib, Bilateral, Accessory Float - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
1(2.2)
1(5.6) |
|
13th rib, Bilateral, Rudimentary - Anomaly |
Fetuses N(%)
Litters N(%) |
2(3.5)
2(9.5) |
0(0.0)
0(0.0) |
2(3.5)
2(10.0) |
1(2.2)
1(5.6) |
|
13th rib, Bilateral, Rudimentary Float - Anomaly |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
1(2.0)
1(5.3) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
13th rib, Bilateral, Extra - Anomaly |
Fetuses N(%)
Litters N(%) |
9(15.8)
5(23.8) |
3(5.9)
3(15.8) |
2(3.5)
2(10.0) |
4(8.9)
3(16.7) |
|
Sternebrae
|
4th & 5th sternebrae, Fused - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
6th sternebra, Hypoplastic - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.8)
1(4.8) |
3(5.9)
3(15.8) |
1(1.8)
1(5.0) |
4(8.9)
3(16.7) |
|
6th sternebra, Incomplete ossification - Variation |
Fetuses N(%)
Litters N(%) |
7(12.3)
6(28.6) |
4(7.8)
3(15.8) |
6(10.5)
4(20.0) |
1(2.2)
1(5.6) |
|
6th sternebra, Poor ossification - Variation |
Fetuses N(%)
Litters N(%) |
6(28.6)
0(0.0) |
3(15.8)
2(3.9) |
4(20.0)
0(0.0) |
0(0.0)
1(5.6) |
|
6th sternebra, Delayed skeletal ossification - Variation |
Fetuses N(%)
Litters N(%) |
1(1.5)
1(4.8) |
0(0.0)
0(0.0) |
1(1.5)
1(5) |
0(0.0)
0(0.0) |
|
6th sternebra, Incomplete ossification - Variation |
Fetuses N(%)
Litters N(%) |
1(4.8)
3(4.5) |
0(0.0)
5(8.5) |
1(5.0)
4(5.9) |
0(0.0)
2(3.6) |
|
5th sternebra, Hypoplastic - Anomaly |
Fetuses N(%)
Litters N(%) |
3(14.3)
14(21.2) |
4(21.1)
15(25.4) |
3(15.0)
17(25.0) |
2(10.0)
8(14.5) |
|
5th sternebra, Delayed skeletal ossification - Variation |
Fetuses N(%)
Litters N(%) |
14(21.2)
9(42.9) |
15(25.4)
12(63.2) |
17(25.0)
11(55.0) |
8(21.1)
15(25.4) |
|
5th sternebra, Poor ossification - Variation |
Fetuses N(%)
Litters N(%) |
6(28.6)
2(3.0) |
9(15.3)*
7(36.8) |
3(4.4)
3(15.0) |
0(0.0)
0(0.0) |
|
5th sternebra, Incomplete ossification - Variation |
Fetuses N(%)
Litters N(%) |
16(24.2)
9(42.9) |
15(25.4)
12(63.2) |
19(27.9)
11(55.0) |
18(32.7)
15(75.0) |
|
4th sternebra, Delayed skeletal ossification - Variation |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
1(1.8)
1(1.5) |
|
2nd sternebra, Hypoplastic - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.5)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
2nd sternebra, Incomplete ossification - Variation |
Fetuses N(%)
Litters N(%) |
4(6.1)
3(14.3) |
4(6.8)
2(10.5) |
3(4.4)
3(15.0) |
2(3.6)
2(10) |
|
Forelimbs |
Metacarpal, middle phalange-5, Delayed skeletal ossification - Variation |
Fetuses N(%)
Litters N(%) |
5(7.6)
3(14.3) |
4(6.8)
2(21.1) |
3(4.4)
3(15.0) |
3(5.5)
2(10.0) |
Carpal bone, Right, Bent, Slight - Anomaly |
Fetuses N(%)
Litters N(%) |
1(1.5)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
|
Skull |
Parietal, Extra suture - Variation |
Fetuses N(%)
Litters N(%) |
1(1.5)
1(4.8) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
Fontanelle, Enlarged - Variation |
Fetuses N(%)
Litters N(%) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
0(0.0)
0(0.0) |
1(1.8)
1(5.0) |
Table 1. Details of Necropsy Findings
Parameters
|
Group No. Dose (mg/kg/day) |
|||
G1 |
G2 |
G3 |
G4 |
|
0 |
50 |
150 |
300 |
|
Total number of mated rabbits / group |
6 |
6 |
6 |
6 |
Duration of treatment (days) |
Gestation Days 6 to 28 (23 days) |
|||
Day of cesarean section (day of presumed gestation) |
29 |
|||
No. of rabbits dead before cesarean section |
0 |
0 |
|
|
No. of rabbits aborted |
0 |
0 |
|
|
No. of rabbits sacrificed at cesarean section |
6 |
6 |
|
|
No. of non-pregnant rabbits at cesarean section |
1 |
1 |
|
|
No. of rabbits pregnant at cesarean section |
5 |
5 |
|
|
No. of litters examined |
5 |
5 |
|
|
|
|
|
|
|
Total no. of fetuses |
36 |
29 |
|
|
Number of fetuses evaluated |
|
|
|
|
a. External |
36 |
29 |
|
|
b. Abnormal fetus |
0 |
0 |
|
|
c. Dead fetus |
0 |
0 |
|
|
NOTE: Dose groups of 150 and 300 mg/kg/day were terminated due to treatment related clinical signs and mortalities.
Table 2. Summary of Clinical Signs and Mortality
Observation Types (Day 0 - 29) | Female G1 (0 mg/kg bw/day) | Female G2 (50 mg/kg bw/day) | Female G3 (150 mg/kg bw/day) | Female G4 (300 mg/kg bw/day) |
Normal | 6 | 6 | 6 | 6 |
Dyspnoea | 0 | 0 | 1 | 0 |
Emaciation | 0 | 0 | 0 | 1 |
Faecal Consistency, Semi solid faeces | 0 | 0 | 1 | 1 |
Dead | 0 | 0 | 2 | 3 |
Killed - humane | 0 | 0 | 2 | 2 |
Killed - moribund | 0 | 0 | 2 | 1 |
Killed - terminal kill | 6 | 6 | 0 | 0 |
Salivation, slight | 0 | 1 | 0 | 0 |
Salivation, moderate | 0 | 1 | 2 | 0 |
Salivation, severe | 0 | 0 | 1 | 1 |
Posture, recumbent | 0 | 0 | 2 | 0 |
Posture, curled up, often asleep or sit | 0 | 0 | 1 | 1 |
Discharge, nose/snout, moderate | 0 | 1 | 1 | 0 |
Discharge, nose/snout, severe | 0 | 0 | 1 | 1 |
Discharge, both eyes, moderate | 0 | 0 | 1 | 0 |
Values = number of animals affected
Table 3. Summary of Maternal Body Weight of Pregnant Rabbits
Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 | Mean SD N |
3.3779 0.1280 5 |
3.4240 0.2227 5 |
3.4754 0.2354 6 |
3.4600 0.2356 6 |
3 | Mean SD N |
3.3764 0.1347 5 |
3.4831 0.2274 5 |
3.5021 0.2788 6 |
3.5099 0.2322 6 |
6 |
Mean SD N |
3.3929 0.1528 5 |
3.5059 0.2566 5 |
3.5213 0.3071 6 |
3.5108 0.2128 6 |
9 |
Mean SD N |
3.3573 0.1097 5 |
3.4228 0.3068 5 |
3.3293 0.3157 6 |
3.2016 0.2277 6 |
12 |
Mean SD N |
3.3500 0.1649 5 |
3.4142 0.4083 5 |
3.2978 0.3809 6 |
2.8931 0.2065 5 |
15 |
Mean SD N |
3.4210 0.1915 5 |
3.3097 0.3066 5 |
3.1593 0.4668 3 |
- |
18 |
Mean SD N |
3.4182 0.1666 5 |
3.3178 0.3154 5 |
3.3481 0.5288 2 |
- |
21 |
Mean SD N |
3.3984 0.1671 5 |
3.3791 0.2912 5 |
- |
- |
24 |
Mean SD N |
3.4366 0.1845 5 |
3.3651 0.2954 5 |
- |
- |
27 |
Mean SD N |
3.4493 0.1364 5 |
3.4244 0.3039 5 |
- |
- |
29 |
Mean SD N |
3.4809 0.1389 5 |
3.4758 0.3078 5 |
- |
- |
Anova & Dunnett(Log)
Table 4. Summary of Maternal Body Weight Gain of Pregnant Rabbits
ABSOLUTE WEIGHT GAIN (kg) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 3 [a] | Mean SD N |
0.0015 0.0518 5 |
0.0591 0.0483 5 |
0.0267 0.0544 6 |
0.0499 0.0409 6 |
3 - 6 [a] | Mean SD N |
0.0166 0.0347 5 |
0.0229 0.0360 5 |
0.0193 0.0584 6 |
0.0009 0.0380 6 |
6 - 9 [a] |
Mean SD N |
0.0357 0.0596 5 |
0.0832 0.1007 5 |
0.1921 0.1181 6 |
0.3092 0.0567 6 |
9 - 12 [a] |
Mean SD N |
0.0073 0.1032 5 |
0.0086 0.1302 5 |
0.0314 0.0902 6 |
0.2454 0.0628 5 |
12 - 15 [a] |
Mean SD N |
0.0711 0.0382 5 |
0.1045 0.1430 5 |
0.0531 0.1206 3 |
- |
15 - 18 [a] |
Mean SD N |
0.0028 0.0403 5 |
0.0081 0.0791 5 |
0.0265 0.0019 2 |
- |
18 - 21 [a] |
Mean SD N |
0.0198 0.0495 5 |
0.0613 0.0442 5 |
- |
- |
21 - 24 [a] |
Mean SD N |
0.0383 0.0478 5 |
0.0140 0.0310 5 |
- |
- |
24 - 27 [a] |
Mean SD N |
0.0127 0.0864 5 |
0.0593 0.0265 5 |
- |
- |
27 - 29 [a] |
Mean SD N |
0.0316 0.0104 5 |
0.0513 0.0242 5 |
- |
- |
[a] ‑ Anova & Dunnett(Log)
Table 4. Cont'd Summary of Maternal Body Weight Gain of Pregnant Rabbits
ABSOLUTE WEIGHT GAIN (kg) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 6 [a] | Mean SD N |
0.0151 0.0692 5 |
0.0819 0.0692 5 |
0.0460 0.0919 6 |
0.0508 0.0721 6 |
6 - 29 [a] | Mean SD N |
0.0879 0.1513 5 |
0.0302 0.2346 5 |
- |
- |
0 - 29 [a] |
Mean SD N |
0.1030 0.1672 5 |
0.0518 0.2692 5 |
- |
- |
Adjusted Bodyweight (kg) GD29 UTWT [a] |
Mean SD N |
3.1070 0.1183 5 |
3.1161 0.2952 5 |
- |
- |
Adjusted BW Gain Adj BwtD6 [a] |
Mean SD N |
0.2860 0.1397 5 |
0.3899 0.2052 5 |
- |
- |
[a] ‑ Anova & Dunnett(Log)
Table 5. Summary of Food Consumption of Pregnant Rabbits
Total Food Consumption (g) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 3 | Mean SD N |
381.36 112.12 5 |
396.98 18.92 5 |
374.82 73.28 6 |
491.52* 47.98 6 |
3 - 6 | Mean SD N |
424.70 86.84 5 |
447.54 43.30 5 |
397.87 77.19 6 |
468.98 72.30 6 |
6 - 9 |
Mean SD N |
255.10 134.85 5 |
248.50 129.72 5 |
100.62 101.65 6 |
24.53 34.12 6 |
9 - 12 |
Mean SD N |
297.34 146.48 5 |
196.98 78.62 5 |
156.68 123.98 6 |
12.62 15.44 5 |
12 - 15 |
Mean SD N |
257.72 130.28 5 |
100.18 56.19 5 |
130.63 171.27 3 |
- |
15 - 18 |
Mean SD N |
268.88 81.16 5 |
158.92* 61.38 5 |
163.45 135.55 2 |
- |
18 - 21 |
Mean SD N |
259.94 66.51 5 |
266.80 100.41 5 |
- |
- |
21 - 24 |
Mean SD N |
245.24 110.32 5 |
226.02 62.26 5 |
- |
- |
24 - 27 |
Mean SD N |
232.44 26.50 5 |
255.40 42.23 5 |
- |
- |
27 - 29 |
Mean SD N |
154.44 68.96 5 |
181.32 63.23 5 |
- |
- |
Anova & Dunnett(Log): * = p < 0.05;
Table 5 Contd. Summary of Food Consumption of Pregnant Rabbits
FOOD MEAN DAILY CONSUMPTION 9g/day) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 3 | Mean SD N |
127.12 37.37 5 |
132.33 6.31 5 |
124.94 24.43 6 |
163.84* 15.99 6 |
3 - 6 | Mean SD N |
141.57 28.95 5 |
149.18 14.43 5 |
132.62 25.73 6 |
156.33 24.10 6 |
6 - 9 |
Mean SD N |
85.03 44.95 5 |
82.83 43.24 5 |
33.54 33.88 6 |
8.18 11.37 6 |
9 - 12 |
Mean SD N |
99.11 48.83 5 |
65.66 26.21 5 |
52.23 41.33 6 |
4.21 5.15 5 |
12 - 15 |
Mean SD N |
85.91 43.43 5 |
33.39 18.73 5 |
43.54 57.09 3 |
- |
15 - 18 |
Mean SD N |
89.63 27.05 5 |
52.97* 20.46 5 |
54.48 45.18 2 |
- |
18 - 21 |
Mean SD N |
86.65 22.17 5 |
88.93 33.47 5 |
- |
- |
21 - 24 |
Mean SD N |
81.75 36.77 5 |
75.34 20.75 5 |
- |
- |
24 - 27 |
Mean SD N |
77.48 8.83 5 |
85.13 14.08 5 |
- |
- |
27 - 29 |
Mean SD N |
77.22 34.48 5 |
90.66 31.61 5 |
- |
|
Anova & Dunnett(Log): * = p < 0.05;
Table 5 Contd. Summary of Food Consumption of Pregnant Rabbits
TOTAL FOOD CONSUMPTION (g) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 6 | Mean SD N |
806.06 194.67 5 |
844.52 46.68 5 |
772.68 142.31 6 |
960.50 118.65 6 |
6 - 29 | Mean SD N |
1971.10 633.14 5 |
1634.12 434.46 5 |
- |
- |
0 - 29 |
Mean SD N |
2777.16 747.07 5 |
2478.64 476.09 5 |
- |
- |
Table 5 Contd. Summary of Food Consumption of Pregnant Rabbits
FOOD MEAN DAILY CONSUMPTION (g/day) Sex: Female Day(s) Relative to Mating |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | G3 (150 mg/kg bw/day) | G4 (300 mg/kg bw/day) | |
0 - 6 | Mean SD N |
134.34 32.44 5 |
140.75 7.78 5 |
128.78 23.72 6 |
160.08 19.77 6 |
6 - 29 | Mean SD N |
85.70 27.53 5 |
71.05 18.89 5 |
- |
- |
0 - 29 |
Mean SD N |
95.76 25.76 5 |
85.47 16.42 5 |
- |
- |
Table 6. Summary of Maternal Data
Sex: Female | G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | ||
Group Size | 6 | 6 | ||
Pregnant | 5 | 5 | ||
Gravid Uterus (g) | [a] | Mean SD N |
373.9 39.4 5 |
359.7 52.6 5 |
Number of Corpora Lutea | [k] | Mean SD N |
9.0 1.0 5 |
8.8 1.3 5 |
Number of Implantations |
[k] |
Mean SD N |
8.0 1.4 5 |
6.6 1.3 5 |
Number of Early Deaths |
[k] |
Mean SD N |
0.4 0.9 5 |
0.6 0.5 5 |
Number of Late Deaths |
[k] |
Mean SD N |
0.4 0.5 5 |
0.2 0.4 5 |
Pre-implantation loss/animal |
[k] |
Mean SD N |
1.00 1.00 5 |
2.20 1.30 5 |
Post-implantation loss/animal |
[k] |
Mean SD N |
0.80 1.30 5 |
0.80 0.45 5 |
With late resorptions |
|
|
2 |
1 |
Total Resorptions |
|
|
0 |
0 |
[a] Anova & Dunnett(Log)
[k] Kruskal Wallis & Wilcoxon
Table 7. Summary of Litter Data
Sex: Female |
G1 (0 mg/kg bw/day) | G2 (50 mg/kg bw/day) | ||
Pregnant | 5 | 5 | ||
Total Number | Sum | 36 | 29 | |
Dead | Sum | 0 | 0 | |
Live Male | Sum | 23 | 16 | |
Mean Fetal Weight (M) (g) | [c] | Mean SD N |
38.54 6.44 5 |
41.53 5.45 5 |
Live Female | Sum | 13 | 13 | |
Mean Fetal Weight (F) (g) | [c1] | Mean SD N |
38.19 6.36 5 |
38.72 6.83 5 |
Total Live | Sum | 36 | 29 | |
Mean Fetal Weight (both sexes) (g) | [c2] | Mean SD N |
38.13 6.26 5 |
40.56 5.74 5 |
% male in group | 64 | 55 |
[c] - Ancova/Anova & Dunnett
{Covariate(s): Number of Live Male Fetuses}
[c1] - Ancova/Anova & Dunnett
{Covariate(s): Number of Live Female Fetuses}
[c2] - Ancova/Anova & Dunnett {Covariate(s): Number of Live Fetuses}
Table 8. Summary of Necropsy Findings
Group No. | G1 | G2 | G3 | G4 |
Dose (mg/kg bw/day) | 0 | 50 | 150 | 300 |
Number of Animals on Study | 6 | 6 | 6 | 6 |
Number of Animals Completed | (6) | (6) | (6) | (6) |
Kidneys: Submitted No visual lesions Enlarged, unilaterla Discoloration, red, bilateral |
(6) 6 0 0 |
(6) 6 0 0 |
(6) 6 0 0 |
(6) 4 1 1 |
Liver: Submitted No visible lesions Pale |
(6) 6 0 |
(6) 6 0 |
(6) 5 1 |
(6) 6 0 |
Stomach: Submitted No visible lesions Focus (i); multifocal Foxus (i); red, multifocal |
(6) 6 0 0 |
(6) 6 0 0 |
(6) 6 0 0 |
(6) 4 1 1 |
Thymus: Submitted No visible lesions Discoloration, red |
(6) 6 0 |
(6) 6 0 |
(6) 5 1 |
(6) 6 0 |
Table 9. Summary of Fetal External Observations
Group Number | G1 | G2 |
Dose (mg/kg bw/day) | 0 | 50 |
No. Litters Examined | 5 | 5 |
No. of Fetuses Examined | 36 | 29 |
Normal Variant | None | None |
Minor Anomalies | None | None |
Major Malformations | None | None |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 60 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rabbit
- Quality of whole database:
- The endpoint is concluded based on a single key study with a Klimish rating of 1. Adequate for classification purposes.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
OECD 414 - (2019): Amyl Cinnamic Aldehyde when administered daily by oral gavage during gestation days (GD) 6 to 28 to presumed pregnant New Zealand White rabbits. This study evaluated the maternal toxicity and adverse effects on development of the embryo and fetus in pregnant female rabbits. 92 mated female rabbits were assigned to four groups. Each group consisted of 23 mated rabbits (G1: vehicle control, G2: low dose, G3: mid dose and G4: high dose). Day 0 of gestation for each individual female rabbit in the study was considered as the day on which mating had occurred. Test item in vehicle (Corn oil) was administered at 0, 15, 30 and 60 mg/kg/day at the dose volume of 1mL/kg body weight. The control group received the vehicle only.
Exposure to the Amyl Cinnamic Aldehyde up to 60 mg/kg bw/day caused no evident toxicity related to clinical signs, body weights, food consumption or gross necropsy findings at any of the doses tested except for one incidental abortion in all treatment groups including vehicle control. The maternal and litter data parameters were unaffected, fetal external, visceral and skeletal examination revealed no signs of teratogenicity up to the highest tested dose of 60 mg/kg/day.
In conclusion, based on the above findings, under the test conditions employed in the study, it was concluded that No - Observed - Effect Level (NOEL) for: Maternal toxicity and fetal developmental toxicity is 60 mg/kg/day.
Mode of Action Analysis / Human Relevance Framework
The test item did not induced any effects on the exposured animals and as such, no mode of action could be deduced.
Justification for classification or non-classification
Based on the available read-across data for alpha-hexylcinnamic aldehyde as well as the target sustance, there are no indications of concerns regarding reproductive toxicity or developmental effects for amyl cinnamic aldehyde. Therefore, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008 (CLP).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.